A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully passed an important early safety trial. Researchers have shared that the drug ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

More encouraging news has been announced about the new, twice-yearly PrEP injection currently undergoing trials. Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has ...

A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

An injectable drug to prevent HIV provides a substantial benefit, according to updated recommendations from the U.S. Preventive Services Task Force (USPSTF). The new recommendations for preexposure ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are complicating the process of getting shots. The new injectable was approved ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...